European phase II study of 20 patients reported in Annals of Oncology
SEATTLE, March 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) today announced the publication, by two European institutions, of results of a limited phase II study of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by administration of Zevalin(R) (Ibritumomab Tiuxetan) in elderly patients (60 years of age or older) with previously untreated diffuse large B-cell lymphoma (DLBCL). In this study, 20 previously untreated elderly patients were treated with a novel combination of six cycles of CHOP chemotherapy followed by Zevalin given six to ten weeks later. The study, which had an overall response rate (ORR) of 100 percent, including a 95 percent complete remission (CR) rate, indicated the efficacy, tolerability, and feasibility of this regimen for these patients. Results of the study were reported in the online edition of February 2008 Annals of Oncology. CTI acquired the U.S. rights to Zevalin in December, 2007.
"Although a small phase II experience, these results in elderly
lymphoma patients treated with Zevalin following CHOP without rituximab
demonstrate high rates of complete remissions and overall survival and are
consistent with the potential to use Zevalin as consolidation therapy in
aggressive lymphoma," noted Jack W. Singer, M.D., Chief Medical Officer of
CTI. "We continue to be impressed with the high rate of conversion of
partial to complete remissions following Zevalin consolidation irrespective
of whether or not rituximab therapy is utilized. This publication
demonstrates this in elderly patients with DLBCL while similar data in
indolent lymphomas were reported at ASH 2007 fr
|SOURCE Cell Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved